Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2020

01-05-2020 | Peritonectomy | Peritoneal Surface Malignancy

Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction

Authors: Aditi Bhatt, MS, MCh., Olivier Glehen, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2020

Login to get access

Abstract

Completeness of cytoreduction is one of the most important prognostic factors impacting outcomes of cytoreductive surgery (CRS). To what extent the surrounding normal peritoneum needs to be removed is not known. We hypothesized that the extent of peritoneal resection should be different for different tumors and performed this study to find evidence to support this rationale. To determine the extent of resection of surrounding tissue for any tumor, the mechanisms of tumor development and spread, tumor morphology, the possibility of finding disease in the surrounding normal tissue, and the pattern of lymph node metastases should be known. Surgical resections also depend on patterns of recurrence and the impact of varying extent of resection on survival. We performed a review of literature pertaining to pathways and patterns of peritoneal cancer spread to determine the scientific basis for the extent of peritonectomy. We also reviewed studies comparing less and more extensive peritoneal resection. There is no consensus on the extent of lymphadenectomy required for most PM. Based on this review, we provide recommendations for the extent of peritoneal resection and the extent of lymph node dissection that should be performed for some common peritoneal tumors and identify areas that require further research. We propose that a systematic method of synoptic reporting of pathological specimens of CRS should be developed to capture information regarding the disease distribution within the peritoneal cavity and morphology of PM from different tumors. This can in future be used to establish standard guidelines for such resections.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Rajan F, Bhatt A. Evolving role of CRS and HIPEC-Current indications. In: Bhatt A (ed) Management of peritoneal metastases: cytoreductive surgery, HIPEC and beyond. New York: Springer; 2018. p. 19–67. Rajan F, Bhatt A. Evolving role of CRS and HIPEC-Current indications. In: Bhatt A (ed) Management of peritoneal metastases: cytoreductive surgery, HIPEC and beyond. New York: Springer; 2018. p. 19–67.
3.
go back to reference Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Boston: Kluwer; 1996:359–74.CrossRef Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Boston: Kluwer; 1996:359–74.CrossRef
4.
go back to reference Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911–9.CrossRef Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911–9.CrossRef
5.
go back to reference Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10:3.CrossRef Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10:3.CrossRef
10.
go back to reference Sadot E, Groot Koerkamp B, Leal JN, Shia M, Gonen M, Allen PJ, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: Surgical technique or biologic surrogate? Ann Surg. 2005;262:476–85, (Discussion 483–5).CrossRef Sadot E, Groot Koerkamp B, Leal JN, Shia M, Gonen M, Allen PJ, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: Surgical technique or biologic surrogate? Ann Surg. 2005;262:476–85, (Discussion 483–5).CrossRef
12.
go back to reference Deraco M, Kusamura S, Corbellini C, Guaglio M, Paviglianiti C, Baratti D. Treatment principles for peritoneal surface malignancies. Minerva Chir. 2016;71(2):124–45. (Epub 2016 Feb 5).PubMed Deraco M, Kusamura S, Corbellini C, Guaglio M, Paviglianiti C, Baratti D. Treatment principles for peritoneal surface malignancies. Minerva Chir. 2016;71(2):124–45. (Epub 2016 Feb 5).PubMed
13.
go back to reference Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–71.CrossRef Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–71.CrossRef
17.
18.
go back to reference Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219(2):109–11.CrossRef Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219(2):109–11.CrossRef
19.
go back to reference Kusamura S, Baratti D, Zaffaroni N, Villa R, Laterza B, Balestra MR, et al. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol. 2010;2(1):12–8.CrossRef Kusamura S, Baratti D, Zaffaroni N, Villa R, Laterza B, Balestra MR, et al. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol. 2010;2(1):12–8.CrossRef
20.
21.
go back to reference Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum. 2007;50:37–42.CrossRef Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum. 2007;50:37–42.CrossRef
22.
go back to reference Kostic Z, Cuk V, Bokun R, Ignjatovic D, Usaj-Knezevic S, Ignjatovic M. Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma. Vojnosanit Pregl. 2006;63:349–56.CrossRef Kostic Z, Cuk V, Bokun R, Ignjatovic D, Usaj-Knezevic S, Ignjatovic M. Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma. Vojnosanit Pregl. 2006;63:349–56.CrossRef
23.
go back to reference Meyers M A. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med. 1973;119:198–206.CrossRef Meyers M A. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med. 1973;119:198–206.CrossRef
24.
go back to reference Shimotsuma M, Shields JW, Simpson-Morgan MW, et al. Morpho-physiological function and role of omental milky spots as omentum associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology. 1993;26:90–101.PubMed Shimotsuma M, Shields JW, Simpson-Morgan MW, et al. Morpho-physiological function and role of omental milky spots as omentum associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology. 1993;26:90–101.PubMed
25.
go back to reference Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. In: Gonzalez-Moreno S (ed) Advances in peritoneal surface oncology. Berlin: Springer, 2007:11–23.CrossRef Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. In: Gonzalez-Moreno S (ed) Advances in peritoneal surface oncology. Berlin: Springer, 2007:11–23.CrossRef
26.
go back to reference Yonemura Y, Endo Y, Obata T, Sasaki T. Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Sci. 2007;98:11–8.CrossRef Yonemura Y, Endo Y, Obata T, Sasaki T. Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Sci. 2007;98:11–8.CrossRef
27.
go back to reference Carmignani CP, Sugarbaker T, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003; 22:465–72.CrossRef Carmignani CP, Sugarbaker T, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003; 22:465–72.CrossRef
29.
go back to reference Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Boston: Kluwer, 1995, p. 80–99. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Boston: Kluwer, 1995, p. 80–99.
33.
go back to reference Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416–24. https://doi.org/10.1245/s10434-012-2237-2.CrossRefPubMed Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416–24. https://​doi.​org/​10.​1245/​s10434-012-2237-2.CrossRefPubMed
34.
go back to reference Sinukumar S, Rajan F, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer. A study by INDEPSO. Eur J Surg Oncol. 2019. https://doi.org/10.1016/j.ejso.2019.02.031.CrossRefPubMed Sinukumar S, Rajan F, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer. A study by INDEPSO. Eur J Surg Oncol. 2019. https://​doi.​org/​10.​1016/​j.​ejso.​2019.​02.​031.CrossRefPubMed
35.
go back to reference Bhatt A, Sinukumar S, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer: a study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO). Eur J Surg Oncol. 2019;45(4):666–71. https://doi.org/10.1016/j.ejso.2019.01.009. (Epub 2019 Jan 9).CrossRefPubMed Bhatt A, Sinukumar S, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer: a study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO). Eur J Surg Oncol. 2019;45(4):666–71. https://​doi.​org/​10.​1016/​j.​ejso.​2019.​01.​009. (Epub 2019 Jan 9).CrossRefPubMed
36.
go back to reference Sammartino P, Biacchi D, Cornali T, et al. Proactive management for gastric, colorectal and appendiceal malignancies: preventing peritoneal metastases with hyperthermic intraperitoneal chemotherapy (HIPEC). Indian J Surg Oncol. 2016;7(2):215–24.CrossRef Sammartino P, Biacchi D, Cornali T, et al. Proactive management for gastric, colorectal and appendiceal malignancies: preventing peritoneal metastases with hyperthermic intraperitoneal chemotherapy (HIPEC). Indian J Surg Oncol. 2016;7(2):215–24.CrossRef
38.
go back to reference Hynninen J, Lavonius M, Oksa S, Grenman S, Carpen O, Auranen A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol. 2013;128: 229–32.CrossRef Hynninen J, Lavonius M, Oksa S, Grenman S, Carpen O, Auranen A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol. 2013;128: 229–32.CrossRef
39.
go back to reference Berger Y, Jacoby H, Kaufmann MI, Ben-Yaacov A, Westreich G, Sharon I, et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26(4):1103–9.CrossRef Berger Y, Jacoby H, Kaufmann MI, Ben-Yaacov A, Westreich G, Sharon I, et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26(4):1103–9.CrossRef
40.
go back to reference Yonemura Y, Canbay E, Ishibashi H, Nishino E, Endou Y, Sako S, et al. 5-Aminolevulinic acid fluorescence in detection of peritoneal metastases. Asian Pac J Cancer Prev. 2016;17(4):2271–5.CrossRef Yonemura Y, Canbay E, Ishibashi H, Nishino E, Endou Y, Sako S, et al. 5-Aminolevulinic acid fluorescence in detection of peritoneal metastases. Asian Pac J Cancer Prev. 2016;17(4):2271–5.CrossRef
42.
go back to reference Koppe MJ, Nagtegaal ID, de Wilt JH, Ceelen WP. Recent insights into the pathophysiology of omental metastases. J Surg Oncol. 2014;110:670–5.CrossRef Koppe MJ, Nagtegaal ID, de Wilt JH, Ceelen WP. Recent insights into the pathophysiology of omental metastases. J Surg Oncol. 2014;110:670–5.CrossRef
44.
go back to reference Kolev V, Mironov S, Mironov O, Ishill N, Moskowitz CS, Gardner GJ, et al. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):979–84. https://doi.org/10.1111/igc.0b013e3181e833f5.CrossRefPubMed Kolev V, Mironov S, Mironov O, Ishill N, Moskowitz CS, Gardner GJ, et al. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):979–84. https://​doi.​org/​10.​1111/​igc.​0b013e3181e833f5​.CrossRefPubMed
45.
go back to reference Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–9.CrossRef Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–9.CrossRef
46.
go back to reference Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303–8.CrossRef Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303–8.CrossRef
47.
go back to reference Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–61.PubMed Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–61.PubMed
48.
go back to reference Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patents with diffuse malignant peritoneal mesothelioma. Eur J Sur Oncol. 2006;32:948–53.CrossRef Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patents with diffuse malignant peritoneal mesothelioma. Eur J Sur Oncol. 2006;32:948–53.CrossRef
53.
go back to reference Sugarbaker PH, Bijelic L. The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Tumori. 2008;94(5):694–700.CrossRef Sugarbaker PH, Bijelic L. The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Tumori. 2008;94(5):694–700.CrossRef
Metadata
Title
Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction
Authors
Aditi Bhatt, MS, MCh.
Olivier Glehen, MD, PhD
Publication date
01-05-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08208-z

Other articles of this Issue 5/2020

Annals of Surgical Oncology 5/2020 Go to the issue